Clinical Trial Update: Hydroxychloroquine Administration for Reduction of Pexophagy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating hydroxychloroquine to reduce pexophagy in Zellweger syndrome and peroxisome biogenesis disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peroxisome Biogenesis Disorders
• Zellweger Syndrome

Drugs mentioned

• Hydroxychloroquine (hydroxychloroquine)

Snippet

Sponsor: The Hospital for Sick Children | Conditions: Zellweger Syndrome, Peroxisome Biogenesis Disorders | Phase 2 | Status: COMPLETED